Contents
GRANULES AT A GLANCE
FY 2021-22 highlights | 02 |
Company overview | 04 |
Our business segments | 06 |
Geographic footprint | 08 |
Journey | 10 |
YEAR IN REVIEW
Key performance indicators | 12 |
Chairman's message | 14 |
LEVERS OF GROWTH
Strengthening the core | 16 |
Building technology platforms | 18 |
Manufacturing excellence | 20 |
Research and development | 22 |
GROWING SUSTAINABLY
ESG approach | 24 |
Environmental performance | 26 |
Social | 28 |
Governance | 30 |
Recognitions | 39 |
STATUTORY REPORTS
Management Discussion and Analysis | 40 |
Board's Report | 52 |
Corporate Governance Report | 70 |
Business Responsibility Report | 92 |
FINANCIAL STATEMENTS
Standalone Financial Statements | 100 | |
Consolidated Financial Statements | 168 | |
Notice of the AGM | 234 | |
Corporate Information | Inside Cover |
Transforming with science and technology
Innovation | Excellence | Sustainability
Science and technology form the backbone of pharma manufacturing.
At Granules India, our spirit of innovation is helping take the business to the next level. Technology will play a critical role in enhancing and optimising capacities, capabilities, processes and quality standards while ensuring cost efficiency for the business and our customers. Extensive and advanced level research and development will keep our product pipeline robust with a diverse range of cost-effective offerings. Excellence is a moving target at Granules. This means that we are continuously calibrating our core and strengthening strategies to deliver more. To become a business that stands for more than profitability and helps create positive impact in
the industry, we are adopting and embedding sustainable practices across our operations. Our core focus remains on transforming with times and to this end, we will continue to overrule the status quo and think anew.
Granules at a glance | Year In review | Levers of growth | Growing sustainably | Statutory Reports | Financial Statements |
FY 2021-22 Highlights
Operational
Granules has the highest generic prescription in terms of absolute growth 17.8% in the US market
6 ANDA approvals from USFDA, and additional approvals for 1 EU dossier and 2 Canadian dossiers
Launched 24 generic products under
GPI label in US
Filed 2 patents in India directed towards new process for manufacturing intermediates and /or APIs, purification and pharmaceutical composition thereof
USFDA approval for generic Prazosin Hydrochloride capsules used for the treatment of high blood pressure
Financial | Environmental | Social | Governance |
` 3,76,492 Lakhs | 3,72,589 KL | 10% | 100% |
Income from Operations | Water consumption | Women employees | Shareholder Grievance |
Resolved | |||
` 72,223 Lakhs | 76,25,239 kwh | 68% | 98% |
EBITDA | Renewable energy share | Permanent workforce | |
Average board meeting | |||
19.2% | 81,111 KL | ` 9.13 Cr | attendance |
EBITDA Margins | Recycled water used | CSR expenditure | 50% |
` 41,276 Lakhs | Independent directors | ||
on board | |||
PAT | |||
` 16.66 | |||
EPS | |||
1.64 | |||
Asset Turnover |
2 | Granules India Limited | Annual Report 2021-22 | 3 |
Granules at a glance | Year In review | Levers of growth | Growing sustainably | Statutory Reports | Financial Statements |
COMPANY OVERVIEW
For quality healthcare that transforms lives
VISION
To be the global leader in pharmaceutical manufacturing by process innovation and unparalleled efficiencies.
VALUES
Integrity
We consistently adhere to moral and ethical principles in our thinking as well as actions while conducting our business
Quality
We strive to maintain the highest standards in our products, processes and system all the time
Granules India Limited is among India's largest pharma manufacturing companies with over three decades of experience in manufacturing high quality pharmaceutical products. We produce Active Pharmaceutical Ingredients (API), Pharmaceutical Formulation Intermediates (PFI) and Finished doses (FD) and the same are marketed across key markets of North America, Europe, India and Latin America. Powered by vertical integration, scale, manufacturing excellence, focused execution and cost leadership through continuous innovation, we offer high quality, affordable medicines to people across the world.
We have built one of the largest PFI and single site FD facilities in the world. Our's is the world's largest Paracetamol API facility. We have state-of-the-art research and development centres in Hyderabad and Virginia.
renti | at | ||||
e | o | ||||
if | |||||
D | r | s | |||
A vertically integrated
business model enabling
our rise as a global
pharma player
Growth-oriented stable | Facilities that can |
portfolio of APIs, PFIs | accommodate capacities |
and FDs to cater to | of 24,640 TPA in PFIs to |
large-scale global | leverage economies |
demand | of scale |
Dedicated and seasoned
MISSION
Our drive to be the best is unparalleled. We will match our drive by partnering with global leaders in
our markets, building lasting relationships, and foundation for mutual growth and success.
Improvement | People |
We systematically enhance | We cultivate a conducive work |
value of our products, | environment where every |
processes and services in | employee feels excited and can |
pursuit of excellence | realise their potential |
Customer Centricity | |
We focus on our energies towards | |
understanding and addressing customer | |
expectations thereby building lasting | |
business relationships |
R&D team focused on developing a diverse range of cost-effective drugs
80+ | 7 | facility in the | 5,000+ | 60+ | 24,640 TPA of PFI |
Largest PFI | 39,360 TPA of API | ||||
Countries where | Manufacturing | world | Employees | ANDA filings | 23.3 Billion dosages of |
we operate | plants | ||||
FD Installed Capacity | |||||
4 | Granules India Limited | Annual Report 2021-22 | 5 |
Granules at a glance | Year In review | Levers of growth | Growing sustainably | Statutory Reports | Financial Statements |
OUR BUSINESS SEGMENTS
Enhancing efficacy. Diversifying oferings.
Over the years, we have established a strong presence across the healthcare value chain. Our global-scale operations within API, PFI and FD will focus on achieving cost efficiencies and continuous innovation to remain on the cutting edge of supply chain, manufacturing and
PHARMACEUTICAL FORMULATION INTERMEDIATES (PFI)
With a batch processing capacity of 6 tonnes, we are among the largest PFI manufacturers in the world. We pioneered the commercialization of PFIs, to optimise cost economics of products. This enabled Granules to become a preferred PFI supplier for some of the most renowned global pharma companies. We use our facilities at Jeedimetla and Gagillapur to process the intermediaries and compress them into finished doses.
Revenue (` in Lakhs)
22%
Revenue from
PFI business
42,140 62,619
84,556
operational efficiency.
FY20 FY21 FY22
ACTIVE PHARMACEUTICAL INGREDIENTS (API)
APIs are a key focus area at Granules, which helped us emerge as the key manufacturer and supplier of Paracetamol, Metformin, Guaifenesin, and Methocarbamol. We are among the most efficient and cost-effective manufacturers in the world, offering a specialized API portfolio. We work to enhance our API manufacturing capabilities to add new products to our portfolio pipeline.
Revenue (` in Lakhs) | ||
81,707 | 91,242 | 97,513 |
FINISHED DOSAGES (FD)
Revenue (` in Lakhs) |
FY20 FY21 FY22
The existing portfolio that includes Caplets, Tablets as well as Press-fit Capsules in Bulk, Blister packs and Bottles contribute to over half of our revenue. They are manufactured at our state-of-the-art facility at Gagillapur. This unit is equipped with automated processes, robust infrastructure and superior quality systems to efficiently produce finished dosages that are marketed across 80+ countries.
52% | ||
Revenue | ||
from FD | 1,94,423 | |
1,36,018 | 1,69,893 | |
FY20 | FY21 | FY22 |
6 | Granules India Limited | Annual Report 2021-22 | 7 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
Granules India Limited published this content on 05 July 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 July 2022 04:52:06 UTC.